Viking Therapeutics (VKTX) Set to Announce Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is scheduled to release its earnings data after the market closes on Wednesday, April 24th. Analysts expect Viking Therapeutics to post earnings of ($0.27) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.25). During the same quarter in the prior year, the business earned ($0.26) EPS. On average, analysts expect Viking Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Viking Therapeutics Stock Performance

NASDAQ:VKTX opened at $63.85 on Tuesday. Viking Therapeutics has a fifty-two week low of $8.28 and a fifty-two week high of $99.41. The firm has a 50-day simple moving average of $66.27 and a two-hundred day simple moving average of $33.96.

Insider Transactions at Viking Therapeutics

In related news, CEO Brian Lian sold 269,079 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $26.87, for a total transaction of $7,230,152.73. Following the completion of the sale, the chief executive officer now directly owns 2,184,882 shares in the company, valued at $58,707,779.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Viking Therapeutics news, CEO Brian Lian sold 269,079 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $26.87, for a total transaction of $7,230,152.73. Following the transaction, the chief executive officer now owns 2,184,882 shares of the company’s stock, valued at $58,707,779.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sarah Kathryn Rouan sold 25,000 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $28.05, for a total transaction of $701,250.00. The disclosure for this sale can be found here. Insiders sold 329,079 shares of company stock worth $8,769,653 over the last three months. 4.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Viking Therapeutics in a research note on Tuesday, March 26th. Raymond James raised their price objective on shares of Viking Therapeutics from $37.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Stifel Nicolaus restated a “buy” rating and set a $80.00 price objective on shares of Viking Therapeutics in a research note on Friday, March 15th. StockNews.com upgraded shares of Viking Therapeutics to a “sell” rating in a research note on Friday, February 9th. Finally, BTIG Research lifted their price target on shares of Viking Therapeutics from $100.00 to $125.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $112.25.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.